1. Home
  2. ESTC vs CRSP Comparison

ESTC vs CRSP Comparison

Compare ESTC & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Elastic N.V.

ESTC

Elastic N.V.

HOLD

Current Price

$51.82

Market Cap

5.6B

Sector

Technology

ML Signal

HOLD

Logo CRISPR Therapeutics AG

CRSP

CRISPR Therapeutics AG

HOLD

Current Price

$54.67

Market Cap

4.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ESTC
CRSP
Founded
2012
2013
Country
Netherlands
Switzerland
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.6B
4.9B
IPO Year
2018
2016

Fundamental Metrics

Financial Performance
Metric
ESTC
CRSP
Price
$51.82
$54.67
Analyst Decision
Buy
Buy
Analyst Count
28
17
Target Price
$91.38
$70.29
AVG Volume (30 Days)
1.4M
1.7M
Earning Date
05-28-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,483,296,000.00
$289,590,000.00
Revenue This Year
$19.06
$807.72
Revenue Next Year
$13.42
$172.52
P/E Ratio
N/A
N/A
Revenue Growth
17.04
9169.85
52 Week Low
$42.05
$34.87
52 Week High
$96.07
$78.48

Technical Indicators

Market Signals
Indicator
ESTC
CRSP
Relative Strength Index (RSI) 57.66 54.56
Support Level $49.44 $50.91
Resistance Level $51.91 $55.30
Average True Range (ATR) 2.20 3.02
MACD 0.74 -0.04
Stochastic Oscillator 83.04 58.44

Price Performance

Historical Comparison
ESTC
CRSP

About ESTC Elastic N.V.

Elastic is a software company that specializes in AI-search, observability, and security deployments. Its search division offers both traditional keyword search and vector search methods to enable more context-aware querying. The software has open-source origins but generates revenue through valuable add-ons, including simplified data orchestration and server scaling techniques.

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

Share on Social Networks: